MONTCLAIR, N.J., June 18, 2012 (GLOBE NEWSWIRE) -- FluoroPharma Medical, Inc. (OTCBB:FPMI), a company specializing in the development of breakthrough molecular imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of pathology before clinical manifestation of diseases, announced today the release of a company overview as presented by FluoroPharma’s President, CEO and Chairman of the Board, Thijs Spoor. This second “State of the Union” address serves to provide shareholders with a perspective on the company, its evolution and future potential.
